nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Cesano, Alessandra ^a  

^a NanoString Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; MESSENGER RNA;

ANGIOGENESIS; ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMOBILIZATION; IMMUNOTHERAPY; METASTASIS; NEOPLASM; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 84997633419     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0088-7     Document Type: Article

References (3)

1. Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using Formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14:177-204.
2. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317-25.
3. Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD1, PD-L1 and CTLA-4. Clin Cancer Res. 2015;21(7):1639-51.